Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

VYGR | Voyager Therapeutics, Inc.

Index	RUT	P/E	3.33	EPS (ttm)	2.28	Insider Own	0.60%	Shs Outstand	43.52M	Perf Week	-4.52%
Market Cap	344.13M	Forward P/E	-	EPS next Y	-2.02	Insider Trans	-8.33%	Shs Float	34.88M	Perf Month	-20.75%
Income	95.80M	PEG	-	EPS next Q	-0.58	Inst Own	61.20%	Short Float / Ratio	5.96% / 5.08	Perf Quarter	-36.30%
Sales	194.90M	P/S	1.77	EPS this Y	36.00%	Inst Trans	0.60%	Short Interest	2.08M	Perf Half Y	1.60%
Book/sh	4.57	P/B	1.66	EPS next Y	-272.60%	ROA	-	Target Price	13.67	Perf Year	25.62%
Cash/sh	6.02	P/C	1.26	EPS next 5Y	-	ROE	-	52W Range	4.77 - 14.34	Perf YTD	24.59%
Dividend	-	P/FCF	-	EPS past 5Y	14.40%	ROI	-86.20%	52W High	-47.00%	Beta	1.08
Dividend %	-	Quick Ratio	6.20	Sales past 5Y	32.20%	Gross Margin	-	52W Low	59.33%	ATR	0.39
Employees	125	Current Ratio	6.20	Sales Q/Q	600.00%	Oper. Margin	-	RSI (14)	27.35	Volatility	4.28% 4.50%
Optionable	Yes	Debt/Eq	0.00	EPS Q/Q	-2.40%	Profit Margin	-	Rel Volume	0.41	Prev Close	7.73
Shortable	Yes	LT Debt/Eq	0.00	Earnings	Aug 03 BMO	Payout	-	Avg Volume	408.90K	Price	7.60
Recom	1.90	SMA20	-15.63%	SMA50	-16.72%	SMA200	-14.38%	Volume	168,989	Change	-1.68%

Date	Action	Analyst	Rating Change	Price Target Change
May-10-23	Initiated	Truist	Buy	$18
Mar-10-23	Initiated	Oppenheimer	Outperform	$14
Oct-07-21	Upgrade	Robert W. Baird	Neutral → Outperform	$6 → $9
Feb-26-21	Downgrade	Robert W. Baird	Outperform → Neutral	$18 → $6
Feb-03-21	Downgrade	Wedbush	Outperform → Neutral	$6
Feb-03-21	Downgrade	BTIG Research	Buy → Neutral
Dec-24-20	Downgrade	Cantor Fitzgerald	Overweight → Neutral	$15 → $10
Dec-23-20	Downgrade	Raymond James	Outperform → Mkt Perform
Nov-11-20	Downgrade	Oppenheimer	Outperform → Perform
Nov-10-20	Downgrade	Wells Fargo	Overweight → Equal Weight	$10
Nov-10-20	Downgrade	Raymond James	Strong Buy → Outperform	$28 → $17
Mar-19-20	Initiated	The Benchmark Company	Buy	$18
Feb-06-20	Initiated	Oppenheimer	Outperform
Nov-15-18	Upgrade	Raymond James	Outperform → Strong Buy
Sep-10-18	Resumed	BTIG Research	Buy	$32
Sep-10-18	Downgrade	Morgan Stanley	Overweight → Equal-Weight
Jun-04-18	Initiated	H.C. Wainwright	Buy	$30
Mar-12-18	Downgrade	Wedbush	Outperform → Neutral	$29
Mar-12-18	Downgrade	Evercore ISI	Outperform → In-line
Feb-02-18	Initiated	Morgan Stanley	Overweight

Show Previous Ratings

Sep-07-23 04:01PM	Voyager Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Aug-30-23 07:00AM	Voyager Therapeutics to Participate in Upcoming Investor Conferences (GlobeNewswire)
Aug-22-23 08:14AM	11 Most Undervalued Biotech Stocks to Buy According to Analysts (Insider Monkey)
Aug-08-23 04:01PM	Voyager Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Aug-07-23 08:00AM	Voyager Therapeutics Announces Appointment of Beth Shafer as Chief Business Officer (GlobeNewswire)
08:25AM	Loading…
Aug-03-23 08:25AM	Voyager Therapeutics (VYGR) Reports Q2 Loss, Tops Revenue Estimates (Zacks)
07:17AM	Voyager Therapeutics: Q2 Earnings Snapshot (AP Finance)
07:00AM	Voyager Therapeutics Reports Second Quarter 2023 Financial and Operating Results (GlobeNewswire)
Aug-02-23 07:00AM	Voyager Therapeutics to Present at the Canaccord Genuity Growth Conference (GlobeNewswire)
Jul-27-23 07:00AM	Voyager Therapeutics Announces Second Quarter 2023 Conference Call and Webcast (GlobeNewswire)
Jul-14-23 05:40AM	2 Biotech Stocks That Could Make You Richer (Motley Fool)
Jul-11-23 08:53PM	Why These 7 Stocks Are the Best Ways to Play Biotech Right Now (InvestorPlace)
04:01PM	Voyager Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Jul-10-23 08:00AM	Voyager Therapeutics Announces Appointment of Jacquelyn Fahey Sandell as Chief Legal Officer (GlobeNewswire)
Jun-21-23 04:49AM	Voyager Therapeutics (VYGR) Moves 7.9% Higher: Will This Strength Last? (Zacks) -9.65%
06:30AM	Loading…
Jun-15-23 06:30AM	Investors in Voyager Therapeutics (NASDAQ:VYGR) have seen stellar returns of 168% over the past year (Simply Wall St.)
Jun-01-23 07:52PM	The 7 Best Stocks Under $15 to Buy in June 2023 (InvestorPlace)
07:00AM	Voyager Therapeutics to Present at the Jefferies Healthcare Conference (GlobeNewswire)
May-25-23 12:29PM	Voyager Therapeutics, Inc.'s (NASDAQ:VYGR) Stock's On An Uptrend: Are Strong Financials Guiding The Market? (Simply Wall St.) -8.79%
May-18-23 06:00AM	Voyager Therapeutics Presents Robust, Multi-Species Results from Preclinical Studies of IV-Delivered, TRACER-Generated Novel Capsids at the ASGCT 26th Annual Meeting (GlobeNewswire)
May-09-23 08:35AM	Voyager Therapeutics (VYGR) Q1 Earnings and Revenues Surpass Estimates (Zacks) +29.48%
07:37AM	Voyager Therapeutics: Q1 Earnings Snapshot (AP Finance)
07:00AM	Voyager Therapeutics Reports First Quarter 2023 Financial and Operating Results (GlobeNewswire)
06:55AM	Voyager Therapeutics Announces Appointment of George Scangos, Ph.D., to Board of Directors (GlobeNewswire)
May-05-23 06:08AM	Revenues Working Against Voyager Therapeutics, Inc.'s (NASDAQ:VYGR) Share Price (Simply Wall St.)
May-03-23 10:25PM	Voyager Therapeutics (VYGR) Surges 11.1%: Is This an Indication of Further Gains? (Zacks) +11.10%
May-02-23 04:30PM	Voyager Therapeutics Announces Multiple Data Presentations at the American Society of Gene and Cell Therapy 26th Annual Meeting (GlobeNewswire)
07:00AM	Voyager Therapeutics Announces First Quarter 2023 Conference Call and Webcast (GlobeNewswire)
Apr-08-23 09:12AM	Companies Like Voyager Therapeutics (NASDAQ:VYGR) Can Afford To Invest In Growth (Simply Wall St.)
Mar-28-23 07:00AM	Voyager Therapeutics Presents New Data Supporting Tau Antibody Program for Alzheimers Disease and GBA1 Gene Therapy Program for Parkinsons Disease at the AD/PD Conference (GlobeNewswire)
08:04AM	Loading…
Mar-12-23 08:04AM	Voyager Therapeutics, Inc.'s (NASDAQ:VYGR) top owners are individual investors with 29% stake, while 23% is held by institutions (Simply Wall St.)
Mar-08-23 03:03AM	Q4 2022 Voyager Therapeutics Inc Earnings Call (Thomson Reuters StreetEvents) +10.76%
Mar-07-23 08:25AM	Voyager Therapeutics (VYGR) Reports Q4 Loss, Misses Revenue Estimates (Zacks) -7.79%
07:00AM	Voyager Therapeutics Reports Fourth Quarter and Full Year 2022 Financial and Operating Results (GlobeNewswire)
Mar-06-23 07:00AM	Voyager Therapeutics to Receive $25 Million Payment for License of Next-Generation AAV Capsids for Multiple Neurologic Disease Targets (GlobeNewswire) +8.89%
Feb-28-23 07:00AM	Voyager Therapeutics Announces Fourth Quarter and Full Year 2022 Conference Call and Webcast (GlobeNewswire)
Feb-13-23 08:00AM	Zacks.com featured highlights include Las Vegas Sands, Voyager Therapeutics and nCino (Zacks)
Feb-10-23 06:23AM	3 Best Stocks to Invest in for Remarkable Earnings Acceleration (Zacks)
Feb-09-23 07:00AM	Voyager Therapeutics to Participate in Upcoming Investor Conferences (GlobeNewswire)
Feb-03-23 04:36AM	Reata Pharmaceuticals, Inc. (RETA) Soars 6.3%: Is Further Upside Left in the Stock? (Zacks) -8.78%
Feb-02-23 06:43AM	Daily Vickers Top Buyers & Sellers for 02/02/2023 (Argus Research) -5.13%
Jan-27-23 07:00AM	Daily Vickers Top Buyers & Sellers for 01/27/2023 (Argus Research)
Jan-24-23 04:01PM	Voyager Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
06:15AM	7 A-Rated Stocks to Buy for Less Than $25 (InvestorPlace)
Jan-20-23 12:08PM	Why Voyager Therapeutics Stock Is Sinking This Week (Motley Fool)
09:55AM	Voyager Therapeutics (VYGR)'s Technical Outlook is Bright After Key Golden Cross (Zacks)
Jan-09-23 01:23PM	Voyager, Neurocrine sign new deal worth up to $4.4B (American City Business Journals)
09:15AM	Neurocrine Biosciences, Voyager Therapeutics Collaborate For Neurological-Focused Gene Therapies (Benzinga)
08:15AM	Voyager, Neurocrine ink gene-therapy deal (MarketWatch)
07:00AM	Neurocrine Biosciences and Voyager Therapeutics Enter Strategic Collaboration for Development and Commercialization of Voyagers GBA1 Program and Other Next-Generation Gene Therapies for Neurological Diseases (GlobeNewswire)
Jan-04-23 07:00AM	Voyager Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Dec-21-22 06:57AM	Those who invested in Voyager Therapeutics (NASDAQ:VYGR) a year ago are up 106% (Simply Wall St.)
Dec-14-22 07:00AM	Voyager Therapeutics Appoints Grace E. Colón, Ph.D., to its Board of Directors (GlobeNewswire) -6.56%
Nov-29-22 04:01PM	Voyager Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Nov-10-22 05:26AM	Voyager Therapeutics Third Quarter 2022 Earnings: Beats Expectations (Simply Wall St.)
Nov-08-22 08:25AM	Voyager Therapeutics (VYGR) Beats Q3 Earnings and Revenue Estimates (Zacks) +9.60%
07:00AM	Voyager Therapeutics Reports Third Quarter 2022 Financial and Operating Results (GlobeNewswire)
Nov-01-22 07:30AM	Voyager Therapeutics Announces Third Quarter 2022 Conference Call and Webcast (GlobeNewswire)
Oct-27-22 10:02AM	NGM Biopharmaceuticals (NGM) Expected to Beat Earnings Estimates: Can the Stock Move Higher? (Zacks)
Oct-25-22 10:01AM	Voyager Therapeutics (VYGR) Expected to Beat Earnings Estimates: Should You Buy? (Zacks)
Oct-18-22 04:01PM	Voyager Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Oct-14-22 08:34AM	Alnylam (ALNY) Soars 3.6%: Is Further Upside Left in the Stock? (Zacks) -7.27%
Oct-11-22 07:00AM	Voyager Therapeutics Presents Data Characterizing a Novel CNS Receptor and Demonstrating the Low-Dose Potential of TRACER Generated Capsid Families (GlobeNewswire) +5.08%
Oct-04-22 11:34AM	Pfizer In-Licenses Voyager Therapeutics' AAV Capsid For Rare Neurologic Disease Target (Benzinga) +17.41%
07:00AM	Voyager Therapeutics Announces Pfizer License of Next-Generation AAV Capsid for Rare Neurologic Disease Target (GlobeNewswire)
Oct-03-22 07:00AM	Voyager Therapeutics Announces Data Presentations at the 29th Annual Congress of the European Society of Gene & Cell Therapy (GlobeNewswire)
06:26AM	Voyager Therapeutics, Inc. (NASDAQ:VYGR) most popular amongst individual investors who own 27% of the shares, institutions hold 26% (Simply Wall St.)
Sep-27-22 07:00AM	Voyager Therapeutics to Participate in Upcoming Investor Conferences (GlobeNewswire)
Sep-22-22 04:01PM	Voyager Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Sep-07-22 07:30AM	Voyager Therapeutics Appoints Peter Pfreundschuh as CFO; Todd Carter, Ph.D., as Chief Scientific Officer; and Trista Morrison as SVP Corporate Affairs (GlobeNewswire) +7.64%
Aug-05-22 11:13AM	Voyager Therapeutics Prioritizes Pipeline With Cash Runway Into 2024 (Benzinga) -7.23%
Aug-04-22 05:15PM	Voyager Therapeutics (VYGR) Reports Q2 Loss, Misses Revenue Estimates (Zacks) +5.66%
04:01PM	Voyager Therapeutics Prioritizes Pipeline and Reports Second Quarter 2022 Financial and Operating Results (GlobeNewswire)
Aug-03-22 11:30AM	Voyager Therapeutics Presents New Data Demonstrating Novel Candidate Therapeutic Antibodies Reduced Tau Pathology in Multiple Preclinical Models (GlobeNewswire) +6.32%
Aug-02-22 04:01PM	Voyager Therapeutics to Present Second Quarter 2022 Results and Corporate Update (GlobeNewswire)
Jul-28-22 07:00AM	Voyager Therapeutics Appoints Catherine J. Mackey, Ph.D. to its Board of Directors (GlobeNewswire)
Jun-09-22 03:23PM	Investors in Voyager Therapeutics (NASDAQ:VYGR) have unfortunately lost 76% over the last three years (Simply Wall St.)
May-19-22 08:38AM	Voyager Therapeutics' TRACER Capsids Show Encouraging Action In Animal Models (Benzinga)
06:00AM	Voyager Therapeutics TRACER Capsids Demonstrate Enhanced CNS Transduction Across Species; New Preclinical Results Bolster GBA1, Tau, SOD1 ALS Gene Therapy Programs (GlobeNewswire)
May-16-22 06:00AM	Voyager Therapeutics to Present Preclinical Data from its Vectorized anti-HER2 Antibody Program and a Novel AAV5-Derived TRACER Capsid at the 25th American Society of Gene and Cell Therapy Annual Meeting (GlobeNewswire)
May-04-22 05:35PM	Voyager Therapeutics (VYGR) Reports Q1 Loss, Misses Revenue Estimates (Zacks)
04:01PM	Voyager Therapeutics Reports First Quarter 2022 Financial and Operating Results (GlobeNewswire)
01:22PM	Blueprint Medicines (BPMC) Q1 Loss in Line, Revenues Top Mark (Zacks)
May-03-22 07:00AM	Voyager Therapeutics Announces Multiple Data Presentations at the American Society of Gene and Cell Therapy 2022 Annual Meeting (GlobeNewswire) +8.14%
May-02-22 11:04AM	Novo Nordisk's (NVO) Q1 Earnings and Sales Beat Estimates (Zacks) +7.23%
Apr-25-22 02:51PM	What Kind Of Shareholders Own Voyager Therapeutics, Inc. (NASDAQ:VYGR)? (Simply Wall St.)
Apr-22-22 01:19PM	Apellis (APLS) Thrives on Empaveli, Stiff Competition a Woe (Zacks)
11:36AM	Intercept (ICPT) Outperforms Industry in 3 Months: What Lies Ahead? (Zacks)
Apr-21-22 07:28AM	Voyager Therapeutics (VYGR) Moves 5.8% Higher: Will This Strength Last? (Zacks) -28.15%
Apr-20-22 10:19AM	KemPharm (KMPH) Starts Early-Stage Cardiovascular Safety Study (Zacks) +5.77%
Apr-18-22 12:45PM	Exelixis (EXEL) Initiates Early Stage Study of Lymphoma (Zacks)
Apr-12-22 02:57PM	Bristol Myers' (BMY) Opdivo Data Positive for Neoadjuvant NSCLC (Zacks)
11:57AM	Curis (CRIS) Down on FDA Partial Clinical Hold on Lymphoma Study (Zacks)
11:47AM	Editas (EDIT) Begins Dosing Pediatric Patients in Gene Drug Study (Zacks)
Apr-08-22 12:26PM	Pfizer (PFE) to Boost RSV Portfolio With ReViral Acquisition (Zacks) -7.42%
11:39AM	Aptinyx (APTX) Tanks as Neuropathic Pain Study Misses Goal (Zacks)
Apr-07-22 02:50PM	Adverum (ADVM) Up on FDA Feedback for Gene Therapy Study (Zacks)
Apr-06-22 12:08PM	Bristol Myers (BMY) Gets EC Nod for CAR T Cell Therapy Breyanzi (Zacks)
11:58AM	Novartis (NVS) Gets FDA Nod for Vijoice in Rare Disorder (Zacks)
Apr-01-22 12:00PM	Voyager Therapeutics (VYGR) Is Up 21.18% in One Week: What You Should Know (Zacks) +9.32%

Voyager Therapeutics, Inc., a biotechnology company, focuses on the treatment of gene therapy and neurology diseases. The company's lead clinical candidate is VY-TAU01, an anti-tau antibody program for the treatment of Alzheimer's disease. It also develops VY-FXN01 to treat Friedreich's ataxia; superoxide dismutase 1 gene silencing program for the treatment of amyotrophic lateral sclerosis; and GBA1 gene replacement program to treat Parkinson's disease. In addition, the company develops research program for the treatment of Huntington's disease. It has collaboration and license agreements with Neurocrine Biosciences, Inc.; Pfizer Inc.; and Novartis Pharma, A.G. for the research, development, and commercialization of adeno-associated virus gene therapy products. Voyager Therapeutics, Inc. was incorporated in 2013 and is headquartered in Cambridge, Massachusetts.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Carter Todd Alfred	Chief Scientific Officer	Sep 15	Option Exercise	2.85	5,000	14,250	64,860	Sep 18 04:44 PM
Carter Todd Alfred	Chief Scientific Officer	Sep 15	Sale	8.16	10,500	85,680	54,360	Sep 18 04:44 PM
Carter Todd Alfred	Chief Scientific Officer	Jul 06	Sale	10.80	5,500	59,400	59,860	Jul 10 04:42 PM
Sandrock Alfred	President and CEO	Apr 03	Sale	7.83	7,437	58,232	214,618	Apr 05 05:04 PM
Swartz Robin	Chief Operating Officer	Apr 03	Sale	7.83	1,259	9,858	71,617	Apr 05 05:02 PM
Hesslein Robert W.	Senior VP & General Counsel	Mar 20	Sale	7.76	4,410	34,222	102,200	Mar 22 04:47 PM
Swartz Robin	Chief Operating Officer	Mar 20	Sale	7.76	3,654	28,355	72,876	Mar 22 04:48 PM
Carter Todd Alfred	Chief Scientific Officer	Mar 20	Sale	7.76	2,193	17,018	65,360	Mar 22 04:49 PM
Swartz Robin	Chief Operating Officer	Mar 15	Sale	8.20	15,373	126,059	76,530	Mar 17 04:37 PM
NEUROCRINE BIOSCIENCES INC	10% Owner	Feb 23	Buy	8.88	4,395,588	39,032,821	8,575,316	Feb 24 06:15 AM
Hesslein Robert W.	Senior VP & General Counsel	Feb 17	Sale	7.45	3,297	24,563	106,610	Feb 22 08:58 PM
Carter Todd Alfred	Chief Scientific Officer	Feb 17	Sale	7.45	738	5,498	67,553	Feb 22 08:57 PM
Hesslein Robert W.	Senior VP & General Counsel	Feb 13	Sale	7.67	2,868	21,998	109,907	Feb 15 04:52 PM
Carter Todd Alfred	Chief Scientific Officer	Feb 13	Sale	7.67	797	6,113	34,291	Feb 15 04:53 PM
Third Rock Ventures III, L.P.	10% Owner	Feb 01	Sale	9.32	128,642	1,198,943	4,685,291	Feb 01 07:26 PM
Third Rock Ventures III, L.P.	10% Owner	Jan 31	Sale	9.25	185,000	1,711,250	4,813,933	Feb 01 07:26 PM
Third Rock Ventures III, L.P.	10% Owner	Jan 30	Sale	9.03	75,000	677,250	4,998,933	Feb 01 07:26 PM
Third Rock Ventures III, L.P.	10% Owner	Jan 27	Sale	9.02	50,000	451,000	5,073,933	Jan 31 04:30 PM
Third Rock Ventures III, L.P.	10% Owner	Jan 25	Sale	9.22	50,000	461,000	5,123,933	Jan 26 05:23 PM
Third Rock Ventures III, L.P.	10% Owner	Jan 24	Sale	9.27	100,000	927,000	5,173,933	Jan 26 05:23 PM
Third Rock Ventures III, L.P.	10% Owner	Jan 23	Sale	9.06	55,000	498,300	5,273,933	Jan 24 06:20 PM
Third Rock Ventures III, L.P.	10% Owner	Jan 20	Sale	9.15	100,000	915,000	5,328,933	Jan 24 06:20 PM
Swartz Robin	Chief Operating Officer	Jan 17	Sale	9.85	2,188	21,549	51,903	Jan 19 04:53 PM
Hesslein Robert W.	Senior VP & General Counsel	Jan 17	Sale	9.85	2,188	21,549	112,775	Jan 19 04:57 PM
Carter Todd Alfred	Chief Scientific Officer	Jan 17	Sale	9.85	1,106	10,892	35,088	Jan 19 04:55 PM
EcoR1 Capital, LLC	10% Owner	Jan 11	Sale	8.50	110,000	934,615	3,851,507	Jan 11 06:26 PM
EcoR1 Capital, LLC	10% Owner	Jan 10	Sale	8.05	336,400	2,709,433	3,961,507	Jan 11 06:26 PM
EcoR1 Capital, LLC	10% Owner	Jan 09	Sale	7.67	456,000	3,498,295	4,297,907	Jan 11 06:26 PM
Carter Todd Alfred	Chief Scientific Officer	Jan 06	Sale	6.41	388	2,487	36,194	Jan 10 04:07 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

VYGR | Voyager Therapeutics, Inc.

Upgrade your FINVIZ experience